ChemPartner PharmaTech Co

ChemPartner PharmaTech Co Gross Margin

The Gross Margin of ChemPartner PharmaTech Co (300149.SZ) as of Oct 27, 2026 is 28.61 %. In the previous year, Gross Margin was 21.80 % — a change of 31.26% (higher).

Gross Margin

28.61 %

YoY

31.26%

Last updated:

Gross Margin of ChemPartner PharmaTech Co is 2025 28.61 % . Gross Margin of ChemPartner PharmaTech Co was 2024 21.80 % . It decreases by 31.26% higher compared to the previous year.

For ChemPartner PharmaTech Co, the gross margin of 28.6% is down versus 31.7% a few years ago.

The ChemPartner PharmaTech Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
42.83 CNY
Jan 1, 2019
38.18 CNY
Jan 1, 2020
38.32 CNY
Jan 1, 2021
31.69 CNY
Jan 1, 2022
25.42 CNY
Jan 1, 2023
25.94 CNY
Jan 1, 2024
21.80 CNY
Jan 1, 2025
28.61 CNY
The ChemPartner PharmaTech Co Gross Margin history
YEARGross MarginYoY
28.61 %+31.26%
21.80 %-15.94%
25.94 %+2.02%
25.42 %-19.78%
31.69 %-17.29%
38.32 %+0.34%
38.18 %-10.85%
42.83 %-6.11%
45.62 %-9.69%
50.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ChemPartner PharmaTech Co Stock analysis

What does ChemPartner PharmaTech Co do? ChemPartner PharmaTech Co., Ltd. generates revenue through the research, development, production, and sale of prebiotic products, primarily fructooligosaccharides and galactooligosaccharides. The company markets its products under the brand names FOS and GOS, targeting the nutrition and health, dairy, beverage, bakery, and functional snack food industries. Domestic distribution dominates, with South China as the core market, serving manufacturers of food and health products. The firm's product portfolio focuses on fructooligosaccharides and galactooligosaccharides, sold as FOS and GOS, which are integrated into various consumer goods. These prebiotics are essential ingredients in dairy, beverages, baked goods, and functional snacks, meeting demand from food producers seeking health-enhancing additives. South China remains the primary sales region, aligning with the company's domestic market strategy. ChemPartner PharmaTech's revenue streams derive from B2B sales to food and beverage manufacturers, particularly those producing nutrition and health products, dairy, and functional snacks. The company's brands FOS and GOS are positioned as key ingredients for health-focused consumer goods, with sales concentrated in South China, the main market for its domestic distribution network. ChemPartner PharmaTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ChemPartner PharmaTech Co stock

Gross Margin of ChemPartner PharmaTech Co is 28.61 % in 2025.

Gross Margin of ChemPartner PharmaTech Co changed from 21.80 % to 28.61 %, representing a 31.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin ChemPartner PharmaTech Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's ChemPartner PharmaTech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — ChemPartner PharmaTech Co

All Key Metrics — ChemPartner PharmaTech Co